Medication Compliance
February 12, 2013
Paperless Documents
February 12, 2013
Show all

Cancer Treatment

Mohsav Maor-based company aims to advance the personalized treatment of cancers common to children, adolescents and young adults.  Lead product is a microRNA-based predictive test for the early prognosis and monitoring of Acute Lymphoblastic Leukemia patients, offering reliable and reproducible, patient-specific results within 2 days of diagnosis vs. up to 12 weeks for currently available MRD tests.  Created at Schneider’s Children’s Medical Center, and clinically validated in three studies.  Seeking investment to support a retrospective clinical trial with a leading US oncology group with results to be used for regulatory approval, finalizing commercial procedures, and marketing material.

Comments are closed.